Furthermore, in subjects with T2DM with established chronic kidney disease (CKD) who received linagliptin in combination with metformin and/or insulin, the randomized controlled trial illustrated a statistically significant improvement of CD34+ EPC migratory function by promoting CD34/CXCR4 activity (30). Here, CXCR4 is linked to chronic kidney disease.